



OPEN ACCESS

EDITED AND REVIEWED BY

Tao Liu,
University of New South Wales, Australia

*CORRESPONDENCE

Weimin Cai
✉ weimincai@fudan.edu.cn

RECEIVED 28 September 2023

ACCEPTED 19 October 2023

PUBLISHED 30 October 2023

CITATION

Zhang J, Tang Z, Guo X, Wang Y, Zhou Y and Cai W (2023) Corrigendum: Synergistic effects of nab-PTX and anti-PD-1 antibody combination against lung cancer by regulating Pi3K/AKT pathway through the *Serpinc1* gene. *Front. Oncol.* 13:1303608. doi: 10.3389/fonc.2023.1303608

COPYRIGHT

© 2023 Zhang, Tang, Guo, Wang, Zhou and Cai. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Corrigendum: Synergistic effects of nab-PTX and anti-PD-1 antibody combination against lung cancer by regulating Pi3K/AKT pathway through the *Serpinc1* gene

Jun Zhang¹, Zhijia Tang¹, Xi Guo², Yunxia Wang¹, Yuhong Zhou² and Weimin Cai^{1*}

¹Department of Clinical Pharmacy, School of Pharmacy, Fudan University, Shanghai, China,

²Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China

KEYWORDS

albumin-bound paclitaxel, combination drug therapy, lung cancer, PD-1, *Serpinc1*

A Corrigendum on

[Synergistic effects of nab-PTX and anti-PD-1 antibody combination against lung cancer by regulating the Pi3K/AKT pathway through the *Serpinc1* gene](#)

By Zhang J, Tang Z, Guo X, Wang Y, Zhou Y and Cai W (2022) *Front. Oncol.* 12:933646. doi: 10.3389/fonc.2022.933646

In the published article, there were errors in [Figures 2, 8](#) as published. In [Figures 2A, B](#), we put the wrong representative plots in the previous [Figure 2](#). [Figures 8D, E](#) showed the rates of migration and invasion with transfection for 24, 48, and 72 h. The third image in the second row of [Figure 8E](#) is the same as the one in the same position of [Figure 8D](#). The image of cell invasion after transfection with *Serpinc1*-OE 48 h in [Figure 8E](#) was wrongly used. The corrected [Figures 2, 8](#) are shown below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.




FIGURE 2 Representative flow cytometric plots of MDSCs in (A) spleen (n = 3, biological duplicates), (B) tumor (n = 5, biological duplicates), and (C) peripheral blood (n = 3, biological duplicates) after treatment with nab-PTX and anti-PD-1 antibody.




FIGURE 8 Effects of *Serpinc1* gene on cell migration, invasion, proliferation, and apoptosis. The transfection of *Serpinc1* was determined using (A) Western blot analysis and (B) qRT-PCR by one-way ANOVA (n = 3). (C) Wound healing assay was measured and analyzed using two-way ANOVA (n = 3, magnification $\times 200$). The rates of (D) migration and (E) invasion were determined with transfection for 24, 48, and 72 h with two-way ANOVA (n = 3, magnification $\times 400$). (F) Colony formation assay (n = 3) and (G) CCK8 assay (n = 5) of *Serpinc1* overexpressing LLC cells were used to determine cell viability with ANOVA. (H) Apoptotic cells post-transfection were detected on flow cytometry using one-way ANOVA (n = 6). *p < 0.05, ***p < 0.001, ****p < 0.0001. Serpinc1-OE, *Serpinc1* overexpression.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.